Weekly signal · NTRA · Healthcare

Natera Inc (NTRA) closes at $322.10 after 20.3% weekly surge

The diagnostics stock’s latest weekly move extended a sharp three-month advance, with turnover running above its recent average.

Natera Inc
Latest322.10 USD
1W move20.3%
Volume1.3x
TrendActive
Diagnostics laboratory equipment with a financial market-data screen in the background.

Market update

What happened

Natera Inc (NTRA) finished the latest week at 322.10 USD, up 20.3% for the week and 19.3% over four weeks. The move sits within a weekly price path over 52 weeks, not an intraday chart.

The advance was supported by elevated activity, with 9.2 million shares traded versus a 13-week average of 7.0 million. Market Dynamics showed confirmation at 1.18, while Relative Strength at 32.9 left the signal set less one-sided despite a 72.8% twelve-week gain.

Continue your research

Explore NTRA across Sharemaestro

These links are shown because current Sharemaestro data is available for this company.

Interactive chartReview weekly price, Trend Line, Fair Value, volume and Relative Strength.Full weekly reportOpen the full company report, financial profile and peer comparison.Technical analysisExamine support, resistance, momentum and the current trend readings.Stage analysisSee whether the stock is basing, advancing, distributing or declining.Trend historyReview how long the current trend has persisted and where it has changed.Sector comparisonCompare sector returns, breadth, leaders and weaker areas.Industry comparisonSee how this company’s industry is performing across its members.Company factorsCompare value, quality, growth, momentum and financial strength.News sentimentSee the balance, quality and freshness of recent company coverage.Buying and selling pressureReview longer-term accumulation, distribution and reversal readings.EarningsReview report dates, estimates, past results and earnings surprises.Options activitySee options positioning, expected move and unusual trading activity.Short interestReview short positioning, crowding and possible squeeze risk.Insider transactionsSee reported purchases and sales by company directors and executives.

NTRA coverage

Evidence context